Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax COIN Option Income Strategy ETF (CONY) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance

YieldMax COIN Option Income Strategy ETFTrade
IDEXX Laboratories, Inc.Trade

Price performance (Past 24H)

Key statistics

YieldMax COIN Option Income Strategy ETF vs IDEXX Laboratories, Inc. — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $18.2, while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.

CONYIDXX
Sector
Income / Options OverlayHealth
52-Week High
$76.50$766.68
52-Week Low
$17.80$526.44
Market Cap
$46.22B
Enterprise Value
$47.12B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax COIN Option Income Strategy ETF

CONY trades at $18.20, up 0.72% with a bearish technical outlook indicated by moving averages. The ETF generates weekly dividend distributions but faces significant price depreciation concerns highlighted in recent financial media coverage. Current RSI levels suggest potential oversold conditions while the stock tests key support at $18.

The outlook remains challenging with negative sentiment surrounding the ETF's strategy and performance. While high dividend yields attract income investors, the underlying price erosion presents substantial risk. Analyst commentary questions the sustainability of returns amid ongoing capital depreciation.

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.

The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About YieldMax COIN Option Income Strategy ETF

CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.

Read more on CONY

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX